Immunetune - Crunchbase Company Profile & Funding

Overview

Immunetune

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

See more interactive data and historical milestones on desktop for the best experience

About Immunetune

Immunetune empower cancer patients’ immune system to fight cancer by enabling durable responses and preventing tumor recurrence.

Closed

Founded

obfuscation

Private

Leiden, Zuid-Holland, The Netherlands

1-10

www.immunetune.com/

Biotechnology

Key People

Sijme Zeilemaker: CEO
Gerben C.M. Zondag: founder & COO

Details

Operating Status

Closed

Company Type

For Profit

Founders

Gerben C.M. Zondag

About the Company

Immunetune is a preclinical-stage biotech developing next-generation DNA vaccines against cancer and infectious diseases. Its proprietary set of technologies allow the rapid, cell-free generation of personalized cancer vaccines encoding multiple (neo-)antigens in linear synthetic DNA with improved immunogenicity through its unique PyroVant™

adjuvant. Its lead cancer vaccine has achieved preclinical Proof of Concept in animal studies and is finalizing its preclinical package with the aim to initiate clinical studies in 2022. Immunetune’s pipeline further consists of infectious disease vaccines, including a pan-corona DNA vaccine, targeting conserved proteins across multiple strains of coronaviruses for global pandemic readiness, currently in preclinical testing.